Abstract：
Clindamycin is a lincosamide-derivate antibiotic that has been widely used both systemically and topically for approximately 5 decades. The antimicrobial profile of clindamycin primarily covers several gram-positive bacteria and anaerobic bacteria, with multiple clinical applications supported in the literature and with widespread real-world use. Topical clindamycin has been used primarily for the treatment of acne vulgaris, with both monotherapy and combination therapy formulations available commercially. This article reviews the use of clindamycin as a topical agent with emphasis on therapy for acne vulgaris, and addresses modes of action, reported anti-inflammatory properties that may relate to therapeutic outcomes, recommendations to avoid the emergence of antibiotic-resistant bacteria, tolerability and safety considerations, and published data from clinical studies completed over a span of several years. A discussion of a newly FDA-approved triple-combination formulation is also included. J Drugs Dermatol. 2024;23(6):438-445. doi:10.36849/JDD.8318.
摘要：
克林霉素是一种林可沙胺衍生的抗生素，已广泛用于全身和局部约50年。克林霉素的抗菌谱主要涵盖几种革兰氏阳性菌和厌氧菌，文献支持多种临床应用，并在现实世界中广泛使用。局部克林霉素主要用于治疗寻常痤疮，单一疗法和联合疗法制剂都是市售的。本文回顾了克林霉素作为外用药物的使用，重点是治疗寻常痤疮。并解决了行动模式，报告的抗炎特性可能与治疗结果有关，建议避免抗生素耐药菌的出现,耐受性和安全性考虑，并发表了几年来完成的临床研究数据。还包括对新的FDA批准的三重组合制剂的讨论。J药物Dermatol。2024；23（6）：438-445。doi:10.36849/JDD.8318。
